1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow pelacarsen: new trials by email Literature Review of pelacarsen trials Research Report on pelacarsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis Pelacarsen (TQJ230) 80mg, Matching placebo - Aortic Stenosis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 502 | 2024-03-07 | 2026-06-23 |
| Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease ISIS 681257, Placebo - Elevated Lipoprotein(a), Cardiovascular Disease | Phase 2 | Completed | Akcea Therapeutics | 286 | 2017-03-07 | 2020-10-30 |
Aortic Valve Stenosis (1) · Cardiovascular Diseases (1) · Dyslipidemias (1) · Hyperlipidemias (1) · Hyperlipoproteinemias (1)
Akcea Therapeutics (1) · Novartis Pharmaceuticals (1)
Canada (2) · Denmark (2) · Germany (2) · Netherlands (2) · United States (2) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Israel (1) · Italy (1) · Portugal (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
PMID 31893580, PMID 32268367, PMID 39329200, PMID 39331470, PMID 42592935
2016 (1)